Is 1061.HK overvalued or undervalued?

1061.HK currently has a P/E ratio of 4.57. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Essex Bio-Technology Limited stock?

Essex Bio-Technology Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 1061.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 1061.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 1061.HK to protect their purchasing power. Because 1061.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 1061.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 1061.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 1061.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks1061.HK

Essex Bio-Technology Limited

HK$2.15+HK$0.07+3.12%

HKSE / HKD

Market cap

HK$1.2B

P/E

4.6

EPS (TTM)

HK$0.06

Dividend yield

5.58%

Beta

0.02

1Y return

-55.30%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$210M2021

$169M2022

$218M2023

$215M2024

$233M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.14Low
Current ratio2.15
Cash ratio1.03
Net margin15.4%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

1061.HK4.6
Healthcare sector median26.8
S&P 50022.0

Trades about 83% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.31
Price to book0.48
EPS (TTM)HK$0.06
Payout ratio2,991%
FCF yield6.16%

Range & risk

HK$2.01HK$4.88

Trading in the lower third of its 52-week band

Beta0.02

Profile

What Essex Bio-Technology Limited actually does

Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.

CEO

Hian Leng Ngiam

Employees

1,240

Headquarters

Zhuhai, GD

Founded

2001-06-27

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 1061.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

1061.HK has a beta of 0.02, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Essex Bio-Technology Limited